Drug profile · INN
methylnaltrexone bromide
RELISTOR
methylnaltrexone bromide (RELISTOR) is a mu opioid receptor antagonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — methylnaltrexone bromide
- US status
- approved
- Class
- Alimentary tract and metabolism (A06)
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
methylnaltrexone bromide (RELISTOR) is a mu opioid receptor antagonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Mu opioid receptor antagonist
Primary target: Mu-type opioid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is methylnaltrexone bromide?
methylnaltrexone bromide (RELISTOR) is a mu opioid receptor antagonist. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for methylnaltrexone bromide?
RELISTOR is a marketed brand name for methylnaltrexone bromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of methylnaltrexone bromide?
methylnaltrexone bromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.